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Background
Description of the condition 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease demonstrated clinical efficacy for of other biological anti-TNF agents for the treatment of CD including (adalimumab, and certolizumab) (Behm 2008), anti-IL-12/23p40 antibodies (ustekinumab, briakinumab) (MacDonald 2016) , anti-α4 Integrin antibody (natalizumab) (MacDonald 2007), anti-α4β7 Integrin antibody (vedolizumab) Lam 2014; ) and recombinant human interleukin-11 for the treatment of CD.
How the intervention might work
An increasingly important issue in CD management is the improvement in QoL, which is consistently and statistically significantly lower in people with CD compared to with the general population (Cosnes 2011; Floyd 2015) . Different dimensions of QoL include Pphysical function, social and emotional well-being, ability to work and freedom from disease symptoms represent dimensions of QoL (Fitzpatrick 1992) . The Hhealth-related quality of life (HRQoL) of adults with CD is impacted by consistently lowered by increased, disease activity which translates into work disability, the number of disease relapses, increased hospitalisation rates and the need for treatment with biologics (van der Have 2014). Conversely, sustained remission is associated with improvement in work productivity and HRQoL (Lichtenstein 2004) . Biological interventions may influence HRQoL in people with CD by increasing the frequency of sustained remission.
HRQoL assessment tools are QoL instruments inclusive of, but not limited to Inflammatory Bowel Disease Questionnaire (IBDQ), Cleveland Global Quality of Life Questionnaire (CGQL), the 36-Item Short-Form Health Survey (SF-36) and European Quality of Life-5 Dimensions (EQ-5D). General forms of HRQoL assessment tools are EQ-5D (Konig 2002) and SF-36 (Ware 1992) . IBDQ (Guyatt 1989; Irvine 1994; Irvine 1996) , SF-36 (Ware 1992 ) and the CGQL (Kiran 2003) are Inflammatory Bowel Disease-specific tools for measuring HRQoL.
The EQ-5D consists of five questions related to the five dimensions: subject's ability to move, self-care, daily activities, pain or discomfort, and psychological condition (Konig 2002) . The scoring system includes a unique five-digit code where each number, from 1 to 5, represents a predefined statement under each of the five dimensions. The SF-36 is a 36 item questionnaire divided into eight domains (physical functioning, role limitations due to physical condition, pain, general wellbeing, vitality, social functioning, mental health and dynamics of the health status over the previous year). An aggregate percentage score is produced for each of the domains, ranging from 0% to 100%, where 0% represents the lowest possible level of functioning (Framework for measuring impact 2012). The IBDQ comprises 32 questions covering bowel function (e.g. loose stool, abdominal pain), systemic function (e.g. fatigue), social function (e.g. work attendance) and psychic function (e.g. depression). A seven-point Likert scale is involved as a scoring system (1 indicating severe issues and 7 no issues) (Feagan 1999) . Total IBDQ score can range from 32 (very poor HRQoL) to 224 (perfect HRQoL) (Irvine 1994) . The CGQL rates current quality of life, current quality of physical, mental, and social well-being and current energy level, each one on a scale from 0 to 10, where 10 indicates best quality scores (Kiran 2003) . Each of these instruments has been extensively validated in IBD patients.
Why it is important to do this review
HRQoL represents a functional effect of the disease and it is one of the main issues in people with CD. Modifying the disease course, the biological treatment may have a substantial effect on HRQoL and therefore would be beneficial to be introduced earlier in the treatment with regard to HRQoL outcomes (Bodger 2002) . Studies increasingly include HRQoL as a secondary outcome and no systematic review has clearly established the evidence for an improvement in HRQoL in this population. A previous literature review on the impact of biologics on HRQoL in IBD patients has been limited in the scope and time of the articles retrieved (IBD population, including both CD and ulcerative colitis) and methodological concept (articles only in English, only IBDQ and SF-36 as outcome measures) (Vogelaar 2009 ). This review endeavours to address an up-to-date critical view of growing evidence on the impact of biological interventions in improving HRQoL in people with CD.
Objectives
To systematically assess the beneficial and harmful effects of the biologic treatment on HRQoL outcomes in people with Crohn's disease.
Methods
Criteria for considering studies for this review Types of studies RCTs assessing the impact of biological interventions on for HRQoL in people with Crohn's disease irrespective of publication status, language, or blinding procedure will be included. We will consider the inclusion of All non-RCTs that report on long-term identified with the search for RCTs will be included only for the report of harms., but not for the report of benefit. Data concerning adverse outcomes from non-RCTs will be reported as descriptive data listed in a special table as a descriptive data and will not be used for in any statistical analysis. Studies that do not measure HRQoL outcomes will be excluded from this review.
Types of participants
Adults people (>18 years of age) with Crohn's disease as defined by a combination of clinical, biochemical, radiological, endoscopic and histological criteria (Van Assche 2010) will be considered for the inclusion ( Van Assche 2010 ).
The clinical criteria include diarrhoea, abdominal pain, weight loss, fever, anal fissures, fistulae, abscesses and extraintestinal manifestations (e.g. skin lesions, arthritis) (Van Assche 2010). The biochemical criteria include leucocytosis, anaemia, elevated erythrocyte sedimentation rate and C-reactive 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease protein, hypoalbuminemia, faecal calprotectin and stool lactoferrin (Van Assche 2010). The radiological criteria include bowel wall thickness of 4 mm or higher, strictures, a conglomeration of loops, fistulae, abscesses, and presence of mural oedema (Kim 2015) . The endoscopic criteria include the discontinuous ulcerations, anal lesions and cobblestoning (Van Assche 2010). The histological criteria include focal chronic inflammation, focal crypt irregularity and granulomas (Magro 2013).
Although there will be no limitations based on for disease activity (i.e. active, or quiescent disease) will be considered for the inclusion, only studies which provide definitions of active disease or and remission based on validated indices will be considered for inclusion. Validated indices for the assessment of disease activity in Crohn's disease include the Crohn's Disease Activity Index (CDAI) (Best 1976) 
Types of interventions
Studies assessing all recognised biological interventions for the treatment of Crohn's disease will be considered for evaluation. These biological interventions include, but are not limited to anti-TNF (infliximab, adalimumab, certolizumab pegol, ) and non-anti-TNF (natalizumab, ustekinumab, briakinumab, vedolizumab, and recombinant human interleukin 10) biologic agents. The comparison will be placebo or an active comparator such as systemic corticosteroids, azathioprine, /6-mercaptopurine or and methotrexate. Serious adverse events present any untoward medical occurrence that results resulted in death, is were life-threatening, requires hospitalisation or causes extension of existing hospitalisationpersistent or lead to a significant disability, or any medical event which had jeopardized the patient or required intervention to prevent it. Non-serious adverse events are defined as any medical occurrence not necessarily causal causally, or related to the treatment, but did, however, require a dose reduction or treatment cessation (ICH 1997; CTCAE 2010) .
Other secondary outcomes include:
2. Improvement in workplace productivity.
3. Improvement in of fatigue.
Search methods for identification of studies Electronic searches
The following databases will be searched: The databases will be searched for RCTs using the search strategies described in Appendix 1.
Searching other resources
The review authors will search the references all citations of all included studies and relevant review articles retrieved by the electronic searches. We and will consider hand searching, particularly when abstracts and conference proceedings of associated meetings are not available online. When information in a published paper is insufficient, we will an attempt to make will be made to contact with the corresponding authors to obtain for additional information.
The following databases will be searched for ongoing trials: If ongoing trials that have not been published are identified by through these searches, the principal investigators and major co-operative groups active in this area will be approached for relevant data.
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Data collection and analysis
Data from included studies will be extracted as described in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Higgins 2011). Data will be analysed using Review Manager 5.3 (Review Manager 2014).
Selection of studies
All studies (titles and abstracts) identified by the literature search will be independently screened for eligibility against inclusion criteria by two review authors (MSB and VG) based on the inclusion criteria described above. We will obtain Ffulltext reports when studies appear to satisfy the inclusion criteria for inclusion based on the title and abstract screening, or when information is insufficient to allow for a decision will be obtained. Any disagreements will be resolved by consensus, or by referring to a third review author (VVP). The number of studies identified, excluded and included, will be reported according to the PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist ).
Data extraction and management
Data extraction will be carried out independently by two authors (MSB, VG) using a standardised data extraction form (Higgins 2011). Where more than one publication of any study exists, reports will be grouped together and the publication with the most complete data will be reported used as the primary study publication. Data from the primary publication will be used for in the data analyses. Any discrepancies between published versions will be highlighted.
The following data will be extracted generated from the original reports:
1. General information: title, authors, journal, year, publication status; 2. Study information: design, risk of bias items (e.g. methods of randomisation, concealment of allocation concealment, and blinding etc.), power calculation, a priori and post hoc analyses; 3. Intervention and control: type and dose of a medication, delivery intervals, comparator; 4. Eligibility: inclusion/ and exclusion criteria, total number screened and randomised; 5. Baseline characteristics (in each group): age, sex, race, disease activity (including the method of evaluation), concurrent medications used and excluded medications.; 6. Follow-up: length of follow-up, assessment of compliance with of treatment, withdrawals and loss to follow-up; and 7. Outcomes: primary and secondary outcomes.
It will be noted in the 'Characteristics of included studies' table if outcome data were not reported in a usable way.
Assessment of risk of bias in included studies
The Cochrane risk of bias tool will be used to assess the methodological quality of included RCTs (Schulz 1995; Moher 1998; Kjaergard 2001; Gluud 2006; Wood 2008) . The risk of bias will be assessed using the following domains:
Random Allocation sequence generation Low risk of bias: We will rate random sequence generation as low risk of bias if aA computer or random number table was used to generated the allocation random sequence. Other Eexamples of random allocation sequence generation methods which will be regarded as adequate include are: drawing lots, tossing a coin, shuffling cards, or throwing dice. Unclear Uncertain risk of bias: We will rate random sequence generation as unclear risk of bias iif the trial was specified as randomised, but the method used for the random allocation sequence generation was not described. High risk of bias: We will rate random sequence generation as high risk of bias iif a method based on a non-random allocation of patients was involved (e.g. dates, names, or admittance numbers). We will exclude high risk of bias These trials will be excluded for the assessment of benefits, but not for harms.
Allocation concealment
Low risk of bias: We will rate allocation concealment as low risk of bias if central randomisation was used or iif an independent unit was used to store allocation information., Examples include an on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes were employed in the patients' allocation concealment process. Unclear Uncertain risk of bias: We will rate allocation concealment as unclear risk of bias iif the trial was specified as randomised, but the method of allocation concealment was not describeddefined. High risk of bias: We will rate allocation concealment as high risk of bias iif the investigators who assigned participants could have been or were informed of the allocation sequence.
Blinding
Low risk of bias: We will rate blinding of participants and personnel as low risk of bias if the trail was reported to be specified as blind, the parties that were blinded, and the method of blinding was clearly described and adequate (e.g. identical placebo)defined. Consequently, the knowledge of allocation was adequately kept in secret during the trial. We will rate the blinding of outcome assessment as low risk of bias if the study clearly reports that outcome assessors were blinded. Unclear Uncertain risk of bias: We will rate blinding of participants and personnel as unclear risk of bias if l the trial was reported to be specified as blind, but the methods to achieve of blinding were not described. was not defined and 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease consequently, the knowledge of allocation was possible during the trial. We will rate the blinding of outcome assessment as unclear risk of bias if the study does not describe the blinding of outcome assessors. High risk of bias: We will rate the blinding of participants and personnel and outcome assessors as high risk if the trial was not blinded so that the allocation was certainly known during the trial (e.g. open label study).
Incomplete outcome data Low risk of bias: We will rate incomplete outcome data as low risk of bias if the numbers of dropouts and reasons for withdrawals are balanced across intervention groups or if and dropouts in all study groups were reported or if it was reported stated that there were no withdrawals or dropouts. Unclear Uncertain risk of bias: We will rate incomplete outcome data as unclear risk of bias if the report does not there was not specifically report on stated that there were no withdrawals or dropouts, although the report gave the impression that there had been no withdrawals or dropouts. High risk of bias: We will rate incomplete outcome data as high risk of bias if the number or reasons for withdrawals and dropouts were not reported stated.
Selective outcome reporting
Low risk of bias: We will rate selective outcome reporting as low risk of bias if the study reports on all outcomes that were pre-defined in the study protocol, or clinically relevant and logically anticipated outcomes (e.g. mortality, systemic inflammatory response syndrome, adverse events) are reported on. Unclear Uncertain risk of bias: We will rate selective reporting bias as unclear if insufficient information is reported to allow for an assessment of selective outcome reporting if not all pre-defined, or clinically relevant and logically anticipated outcomes are reported on or are reported partially, or it is unclear whether details on these outcomes were observed or not. High risk of bias: We will rate selective reporting bias as unclear if the study does not report on all outcomes that were pre-specified in the study protocol, or if the study only partially reports on pre-specified outcomes, or if the study reports on post hoc subgroup analyses without identifying these subgroups as post hoc. We will also rate selective outcome reporting as high risk of bias if one or more clinically relevant and logically anticipated outcomes were not reported on and data for on these outcomes were likely to have been observed (i.e. when no study protocol is available).
Other bias Low risk of bias: We will rate other bias as low risk of bias if the trial gives the impression of being free of bias in other bias domains including: other vested interests, no baseline imbalance across groups in sociodemographic characteristics (e.g. educational level, socio-economic status, ethnicity). Unclear Uncertain risk of bias: We will rate other bias as unclear if the trial does not provide information, transparent or implied, on bias in other domains. High risk of bias: We will rate other bias as high risk of bias if other factors in the trial exist that could impose a risk of bias: other vested interests, (e.g. baseline imbalance across groups in sociodemographic characteristics).
All included trials will be assessed for risk of bias. If the risk of bias in a trial is rated estimated as 'low' for in all of the aboveindicated domains, the trial will be judged as having a 'low risk of bias'. If the risk of bias was estimated as 'unclear' or 'high', then the trial will be judged as having 'high risk of bias'.
The risk of bias for each study will be assessed independently by two review authors (MSB, VG)using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Higgins 2011). If evidence of data concerning for profit bias or and academic bias are found will be reported in the included studies, this will be reported in the characteristics of included studies tables. they will be evaluated in the risk of bias tool under 'Other bias'. The 'Rrisk of bias' judgments will be summarized across different studies for each of the domains indicated above. Any disagreement will be resolved by discussion and consensus involving a the third author (VVP). The authors of original reports will be contacted in the case that published data are unclear or missing.
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Criteria (Guyatt 2011; Schünemann 2011) will be employed to determine the overall quality of evidence supporting the primary and secondary outcomes ( Guyatt 2011 ; Schünemann 2011 ) . Evidence from RCTs begins as high-quality evidence, but they can be downgraded on grounds of: (1) risk of bias, (2) indirectness of evidence, (3) inconsistency (i.e. unexplained heterogeneity), (4) imprecision of effect estimates (i.e. sparse data) and (5) publication bias. The overall quality of evidence for each outcome will be determined and classified as a high quality (i.e. further research is very unlikely to change our confidence in the estimate of effect); a moderate quality (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); a low quality (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); or and a very low quality (i.e. we are very uncertain about the estimate) (Guyatt 2008; Schünemann 2011 ). We will use Tthe GRADE profiler software ( http://gradepro.org/) will be used to import and analyse data from Review Manager and produce the 'Summary of findings' tables.
Measures of treatment effect
For continuous outcomes, we results will calculate be summarised as the mean difference (MD) and corresponding 95% confidence interval (95% CI) if the same tool has been used to measure the same outcome across different studies. We will calculate or the standardized mean difference (SMD) when where the different tools have been used to measure the same underlying construct. employed for measurement of the same outcomes. A For dichotomous outcomes, we will calculate the risk ratio (RR) and corresponding 95% CIwill be involved to summarise the results of dichotomous outcomes. Where studies report described adverse events as dichotomous data, we will report on they will be reported as the proportion of participants experiencing the event in each study arm. and these will be summarised as RR with the corresponding 95% CI. We will report descriptive Rresults for adverse event data that cannot be extracted as dichotomous outcomes will be reported as 'other data' descriptively and will not be included in the meta-analysis if they will be non-extractable as described above (Higgins 2011).
Unit of analysis issues
If there are multiple observations for the same outcome, is described by multiple observations, we will make an effort to combine outcomes for fixed follow-up intervals will be made. We plan to evaluate the outcomes at the maximum follow-up as defined by individual studies. For cross-over trials, we will use The derivable data from the first phase of the cross-over trials (i.e. before any cross-over) will be criteria for the inclusion of these studies. HRQoL outcomes and safety among different doses of biological drugs will be compared using in additional subgroup analyses where if it will be possible. Studies with control groups using different types of interventions (e.g. placebo or active treatment), studies with cluster randomized treatment groups and studies with multiple treatment groups e.g. dose groups) will be analysed separately and will not be combined in a single meta-analysis.
Dealing with missing data
We will attempt to contact the authors of included studies to obtain missing data, if any. In the case of missing data despite our attempts to contact authors, the following strategies will be considered:. For In case of missing data for dichotomous outcomes, two scenarios will be considered., the Bbest-case scenario in which all patients with incomplete data will be assumed to be a treatment success with regard to QoL and a worst-case scenario in which all patients with incomplete data will be assumed to be treatment failures with regard to QoL. We will use sensitivity analysis to assess the impact of these assumptions on the effect estimate. We will use an In case of missing data for continuous outcomes, available case analysis for missing continuous outcomes will be used and assumptions about participants with missing data will not be made. We will contact the Aauthors of studies published in abstract forms only will be contacted for the relevant missing data and these studies will only be included in the review only if enough data are provided to assess outcomes and risk of bias.
Assessment of heterogeneity
We will assess Hheterogeneity across between the effect sizes of the included studies will be assessed by using the Chi 2 test. A P value of 0.10 will be considered to be statistically significant (with a p-value <0.1). The degree of heterogeneity, as a percentage of total variation across trials that results from heterogeneity rather than chance, will be described using the I 2 statistics. We will interpret the I 2 statistic as followsBackground for the interpretation of the I² results will be: 0% to 14% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% represents representing considerable heterogeneity (Higgins 2011). If a considerable degree of heterogeneity is detected (i.e. l 2 > 75%), data will not be pooled for meta-analysis. A fixed-effect model will be used to pool data in the absence of heterogeneity. A random-effects model will be used to pool data if significant heterogeneity is detected.
Assessment of reporting biases
We will assess reporting bias by comparing Comparison of the outcomes listed in study the protocols to those reported in the of published studies. or in the methods sections, iIf protocols are not available, we will compare the to outcomes specified in the the methods section of the published report to those reported in the results section of the manuscript. will serve for the assessment of reporting bias. If more than 10 studies are included in a the pooled analyses, we will explore the potential for publication bias by constructing will be explored by funnel plots (Egger 1997).
Bias introduced by multiple publications will be confronted by including study results only once in a given analysis. If there is reasonable doubt that two publications report results from the same study, we will attempts will be made to contact the trial authors aiming to clarify the issue. Location and language bias will be addressed by searching multiple databases, including non-English language journals.
Data synthesis
The pooled RR and 95% CI will be calculated for dichotomous outcomes and the pooled MD or SMD and 95% CI for continuous outcomes. Data from individual trials will be amalgamated for meta-analysis when the interventions, patient populations, and outcomes are sufficiently similar (to be determined by consensus). A fixed-effect model will be used to pool data in the absence of heterogeneity. A random-effects model will be used if significant heterogeneity is detected (Jakobsen 2014).
Subgroup analysis and investigation of heterogeneity Data permitting, we will perform A subgroup and sensitivity analyses will be employed to investigate substantial heterogeneity if it will be detected and enough data exists to perform such an analyses.
Potential A subgroup analyses include analysis will be carried out according to: trials with a low risk of bias compared to trials with a high risk of bias; biologic-naive patients versus patients who had already been receiving biologic treatment; biologic interventions with placebo versus biologic interventions versus active comparator;
211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease anti-TNF versus non-anti-TNF agents; and different doses of the biological drugs.
Sensitivity analysis
Data permitting, we plan the following sensitivity analyses:
Tthe exclusion of studies published in the abstract form only; and the exclusion of and studies of low methodological quality (i.e. high risk of bias). will be parts of planned sensitivity analyses.
We will also plan to explore potential explanations for heterogeneity using a sensitivity analysis with any excluding any obvious outliers upon forest plot visual inspection of the forest plot. 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease
Results
